Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. Signal., 2 July 2013
Vol. 6, Issue 282, p. ra53
[DOI: 10.1126/scisignal.2003926]

RESEARCH ARTICLES

Estrogen Alters the Splicing of Type 1 Corticotropin-Releasing Hormone Receptor in Breast Cancer Cells

Suchita Lal1, Anna Allan1, Danijela Markovic2, Rosemary Walker3, James Macartney1, Nick Europe-Finner4, Alison Tyson-Capper4, and Dimitris K. Grammatopoulos1*

1 Division of Metabolic and Vascular Health, Warwick Medical School, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK.
2 Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
3 Department of Cancer Studies & Molecular Medicine, Clinical Sciences Building, University of Leicester, Leicester Royal Infirmary, Leicester LE2 7LX, UK.
4 Reproductive and Vascular Biology Group, Institute of Cellular Medicine, The Medical School, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.

Abstract: Hormonal stress response is associated with the pathogenesis of disease, including cancer. The role of the stress hormone CRH (corticotropin-releasing hormone) in breast cancer is complex, and its abundance and biological activity may be modulated by estrogen. In the estrogen receptor–positive (ER+) malignant mammary epithelial cell line MCF7, CRH activated numerous kinases and downstream effectors, at least some of which were mediated by the CRH receptor type 1 (CRH-R1). CRH also increased the transcription of many genes that encode effectors, transcriptional targets, or regulators associated with estrogen signaling. Estrogen increased the abundance of the mRNA encoding CRH-R2 and an alternative splice variant encoding CRH-R1 in which exon 12 was deleted [CRH-R1({Delta}12)]. Estrogen inhibited the expression SRSF6, which encodes serine/arginine-rich splicing factor 55 (SRp55). An increase in CRH-R1({Delta}12), in response to either estrogen or SRp55 knockdown, dampened the cellular response to CRH and prevented its inhibitory effects on cell invasion. SRp55 knockdown also induced additional splicing events within exons 9 to 12 of CRH-R1, whereas overexpression of SRp55 prevented estrogen-induced generation of CRH-R1({Delta}12). ER+ breast tumors had increased CRH-R2 and CRH-R1({Delta}12) mRNA abundance, which was associated with decreased abundance of the mRNA encoding SRp55, compared with the amounts in ER tumors, suggesting that estrogen contributes to the pathophysiology of ER+ breast cancer by altering CRH receptor diversity and disrupting CRH-mediated signaling.

* Corresponding author. E-mail: d.grammatopoulos{at}warwick.ac.uk

Citation: S. Lal, A. Allan, D. Markovic, R. Walker, J. Macartney, N. Europe-Finner, A. Tyson-Capper, D. K. Grammatopoulos, Estrogen Alters the Splicing of Type 1 Corticotropin-Releasing Hormone Receptor in Breast Cancer Cells. Sci. Signal. 6, ra53 (2013).

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
2013: Signaling Breakthroughs of the Year.
J. D. Berndt and N. R. Gough (2014)
Science Signaling 7, eg1
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882